Clinical Trials Browser

Phase 2 × Hematologic Neoplasms × Dasatinib × Clear all

NCT04439305 2020-07-20

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Phase 2 Withdrawn

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms